Navigation Links
IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
Date:8/27/2007

gs Advisory Committee (ODAC) voted 12 to 2 that the data in the NDA do not provide substantial evidence of effectiveness of L-MTP-PE in the treatment of patients with non-metastatic, resectable osteosarcoma receiving combination chemotherapy.

IDM Pharma also is seeking marketing approval from the European Medicines Agency (EMEA) for the use of L-MTP-PE, or MEPACT as it is known in Europe. L-MTP-PE was granted orphan drug status in Europe in 2004. The Marketing Authorization Application (MAA) for L-MTP-PE was submitted to the EMEA on November 1, 2006 and accepted for review on November 27, 2006. The EMEA application is currently under review and the Company continues to work closely with the regulatory body to ensure it has the information needed to approve L-MTP-PE

About Osteosarcoma

About 3% of all childhood cancers are osteosarcoma. Because osteosarcoma usually develops from osteoblasts, it most commonly affects children and young adults experiencing their adolescent growth spurt. Boys and girls have a similar incidence rate until later in their adolescence, when boys are more commonly affected. While most tumors occur in larger bones, such as the femur, tibia, and humerus, and in the area of the bone that has the fastest growth rate, they can occur in any bone. The most common symptom is pain, but swelling and limited movement can occur as the tumor grows.

Osteosarcoma is an orphan disease with fewer than 1,000 new cases diagnosed in the U.S. each year. A similar incidence of the disease exists in Europe. According to the Children's Oncology Group, the survival of children with osteosarcoma has remained at 60-65% since the mid-1980s. The standard treatment for osteosarcoma is tumor resection with combination chemotherapy before and after surgery.

About IDM Pharma

IDM Pharma is focused on the development of innovative cancer products that either destroy cancer cells by activating the immune system or prevent tumor recurrence by
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Analyzing Trace-Level Impurities of a Pharmaceutical Intermediate Using an LCQ Deca Ion Trap Mass Spectrometer and the Mass Frontier Software Package
2. Rapid SNP Genotyping of the Pharmacogenomically Important Allele CYP2D6*4 Using Real-Time qPCR on the DNA Engine Opticon 2 System
3. Development of a sensitive enzyme fragment complementation assay for cyclic adenosine 3, 5 monophosphate and its validation for pharmacological screening at G protein-coupled receptors
4. Practical Applications of HyperDSC in a Pharmaceutical Laboratory
5. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
6. Germantown drug company hires pharma veteran James Davidson as COO
7. Deltanoid Pharmaceuticals begins phase II osteoporosis study
8. New angel capital centered on GenTel agreement with big pharma
9. The deconstruction of Big Pharma
10. Big pharma seeks Wisconsin biotech partnerships
11. Doing the pharmaceutical tango
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 21, 2013 According to a ... http://www.transparencymarketresearch.com ) "Biochip Products and Services Market (Microarrays, Reagents, ... Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018," the market ... is expected to grow at a CAGR of 10.1% ... of USD 4.7 billion in 2018. Browse ...
(Date:5/21/2013)... 2013  Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer ... infectious diseases, announced today that Jeffrey Riley ... Marcum LLP MicroCap Conference on Thursday, May 30, 2013 in ... Hyatt Hotel. Mr. Riley is scheduled to present at 10:00 ... Biologics, presentation can be accessed by logging onto the web ...
(Date:5/21/2013)... May 21, 2013 Inflamax scientists ... the ITN to design the study, which will ... key clinical models used in the study of ... Nasal Allergen Challenge (NAC) models. Although both the ... publications, to date no direct comparison between the ...
(Date:5/21/2013)... Lake, MN (PRWEB) May 21, 2013 The ... trade show display solution for sales and marketing teams looking ... Displays describes the kit as “everything you’ll need to ... Fusion Fabric Display Kit comes with a number of displays ... all-around trade booth 20 feet by 20 feet in size. ...
Breaking Biology Technology:The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 2The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 4The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 5Synthetic Biologics to Present at the 2nd Annual Marcum LLP MicroCap Conference 2Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation. 2GLM Displays Announces All-in-One Formulate Fusion Fabric Display Kit 2
... - EastMed Inc., the medical manufacturing company that caters ... clearance to market its flagship product, uresta(TM) Continence Care, ... to get the official word from the FDA," said ... (TM) Continence Care offers an innovative and cost-effective option ...
... Nov. 25 /PRNewswire/ - Aegera Therapeutics Inc. today announced ... the XIAP antisense oligonucleotide, AEG35156, will be highlighted in ... the American Society of Hematology (ASH) in San Francisco, ... presentation is entitled "Phase I/II Trial of the XIAP ...
... a business unit of DSM Pharmaceutical Products, and Dutch,biotechnology company ... today announced that Hungary-based Gedeon Richter Plc. signed a,commercial license ... the PER.C6(R) platform. , ... About PER.C6(R) technology , ...
Cached Biology Technology:Aegera Therapeutics' phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting 2Aegera Therapeutics' phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting 3DSM Biologics and Crucell Announce Commercial PER.C6(R) Licensing Agreement with Gedeon Richter 2DSM Biologics and Crucell Announce Commercial PER.C6(R) Licensing Agreement with Gedeon Richter 3DSM Biologics and Crucell Announce Commercial PER.C6(R) Licensing Agreement with Gedeon Richter 4
(Date:5/21/2013)... largest scientific society, invites news media coverage of ... 2013, in Indianapolis, Ind. It will take place ... hotels. , With more than 7,100 presentations on ... astronomy to zoology ― the meeting will offer ... of spot news and feature possibilities. The topics ...
(Date:5/21/2013)... which alter the way genes function without changing ... in the blood of pregnant women during any ... depression in the weeks after giving birth, and ... , The findings of the small study involving ... journal Molecular Psychiatry . , "Postpartum depression ...
(Date:5/20/2013)... suggests that a compound abundant in the Mediterranean diet ... , By altering a very specific step in gene ... cells that die as scheduled. , One way that ... would cause them to die on a regular cycle ... cells, led by Ohio State University researchers, found that ...
Breaking Biology News(10 mins):Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3The compound in the Mediterranean diet that makes cancer cells 'mortal' 2The compound in the Mediterranean diet that makes cancer cells 'mortal' 3
... -- Strong evidence developed at Harvard School of Public ... an important contributor to the epidemic rise of obesity ... with these growing public health threats, experts from the ... schools, worksites and homes must take action to help ...
... may explain their ability to respond to regulatory inputs ... series of companion articles from the FANTOM4 consortium. This ... Central,s open access journals, including Genome Biology ... HCNE (highly conserved non-coding element) mediated long-range gene regulation ...
... Virginia Beach, a graduate student in Virginia Tech,s ... Rachel Carson Award for Scientific Excellence from the ... biologist at the agency,s White Sulphur Springs National ... who demonstrate superior scientific involvement and application to ...
Cached Biology News:Nutrition experts propose new class of low-sugar drinks to help stem obesity and diabetes epidemics 2Nutrition experts propose new class of low-sugar drinks to help stem obesity and diabetes epidemics 3FANTOM findings boost for biologists 2
... II RNase H- Reverse Transcriptase (RT) is ... H- RT. It is a DNA polymerase ... single-stranded RNA DNA or an RNA:DNA hybrid. ... introduction of point mutations rather than a ...
... (PNK) catalyzes the transfer of the ... of single- and double-stranded DNA, RNA, ... removes the 3'-phosphate from 3'-phosphoryl polynucleotides, ... to form a 3'-hydroxyl group. Storage ...
MOUSE ANTI GTP BINDING PROTEIN...
We offer solid and solution phase peptide synthesis including a whole range of modifications. Please send the details of your peptide synthesis need to info@rpeptide.com...
Biology Products: